SELLAS Life Sciences (SLS)

• Market cap: $217M
• 1 day: 4.11%
• 5 days: 7.8%
• 1 month: -20.42%
• 3 months: -13.64%
• 6 months: -10.59%
• Year to date: 42.06%
• 1 year: 24.59%
• 5 years: -50.33%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Employees: 15